Drugs / Lucerastat
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03832452 | Feb → Apr 2019 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03380455 | Jan 2018 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02930655 | Feb 2015 → Feb 2016 | Fabry disease | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02944474 | Dec 2003 → May 2004 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02944487 | Oct → Dec 2002 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03737214 | Dec 2018 → Aug 2029 expected | Fabry disease | Idorsia Pharmaceuticals Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03425539 | Jun 2018 → Aug 2021 | Fabry disease | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lucerastat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02944474 ↗ |
| Known as | ACT-434964 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086997 ↗ |
| Known as | N-butyldeoxygalactonojirimycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086997 ↗ |
| Known as | N-n-butyl deoxygalactonojirimycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086997 ↗ |
| Action | Inhibit | “Lucerastat, an inhibitor of glucosylceramide synthase” PMID 28088251 ↗ Jan 20171“Ceramide glucosyltransferase inhibitor” CHEMBL1086997 ↗ |
| Modality | Small molecule | “Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders” PMID 28088251 ↗ Jan 2017 |
| Route | Oral | “Ten subjects with Fabry Disease received 1000 mg of oral lucerastat twice daily for 12 weeks” NCT02930655 ↗ |
| Target | UGCG | “Ceramide glucosyltransferase inhibitor” CHEMBL1086997 ↗ |